Under the agreement, TapImmune has the option to acquire three follow-on technologies developed at the University of British Columbia (UBC) that fall under the scope of the original acquisition completed in 2007.
These technologies broaden the scope and pipeline of products the company intends to develop around its core TAP molecule based vaccines.
Denis Corin, CEO of TapImmune, said: “We are very pleased to be able to continue to strengthen our pipeline of technologies and our IP position around our key TAP technologies.”